Cancer
ESMO21: Latest Clinical Studies Answer Central Questions in the Treatment of Leading Cancers
2021-09-22
Day 2 ESMO 2021 Roundup: New Paradigms for Long-Term Cancer Care and Immunotherapies for High Risk Metastatic Cancers
2021-09-19
Day 1 ESMO 2021 Roundup: Investigational Immunotherapies Show Promise in Early Cancer Trials
2021-09-18
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
2021-09-06
J&J’s FDA-Approved Bispecific Antibody Registers Promising Phase 1 Results for a Different Indication
2021-08-20
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115